Insider transaction details
George Eric Davis, who serves as Executive Vice President and Chief Legal Officer at BioMarin Pharmaceutical Inc (NASDAQ: BMRN), executed a sale of 26,061 shares of the company’s common stock on February 26, 2026, at a per-share price of $61.36. The total proceeds from that sale were approximately $1.6 million. The sale price was close to BioMarin’s then-trading price of $61.11 and the company carries a market capitalization reported at $11.77 billion.
Per a Form 4 filing with the Securities and Exchange Commission, Davis also made purchases of BioMarin common stock on February 25, 2026, acquiring 6,177 shares, 6,675 shares and 2,372 shares on that date. After the February 26 sale, Davis directly holds 72,453 shares of BioMarin stock.
Recent financial performance
BioMarin reported fourth-quarter 2025 results that were mixed versus expectations. Earnings per share came in at $0.46, below the forecast of $0.77, a negative surprise of 40.26%. Revenue for the quarter totaled $875 million, which exceeded analysts’ expectations by 5.51%.
Corporate developments and analyst reactions
The company’s recent strategic activity includes the announced acquisition of Amicus Therapeutics, an item that has attracted investor attention. Following the quarter and corporate developments, several sell-side analysts adjusted their price targets and ratings on BioMarin.
Specifically, Canaccord Genuity raised its price target to $104 and kept a Buy rating, citing a modest top-line beat in the quarter. Bernstein SocGen Group increased its target to $94 and maintained an Outperform rating, while noting that guidance related to the company’s Voxzogo product fell short of expectations. H.C. Wainwright lowered its price target to $55, citing competitive pressure on VOXZOGO. Stifel raised its target to $68 and maintained a Hold rating, referencing perceived value from the Fold deal.
Third-party valuation and platform commentary
An InvestingPro analysis included with reports noted that BioMarin appears undervalued at current price levels, with the platform’s Fair Value calculation suggesting significant upside potential. The same InvestingPro commentary assigned BioMarin a "GREAT" financial health score and referenced nine additional InvestingPro Tips and further analysis available to subscribers.
Context and limitations
The filings and reported results provide discrete data points on insider activity, quarterly performance and analyst positioning. The documentation shows the precise share counts and prices for Davis’s transactions, the specific EPS and revenue figures for the fourth quarter of 2025, and the exact price-target moves and ratings issued by named analysts. Where information is limited in the filings and reports, the article reflects those reported facts without extrapolation beyond the disclosed items.